The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Drugs used for the treatment of hypertension and for management of angina are discussed here. Their major mechanisms of action, key pharmacokinetic principles essential for safe use and important adverse effects are explained. Each class of drug is also given context for effective clinical use.
Drugs used to treat hyperlipidaemias, to reduce platelet aggregation and to achieve thrombolysis are discussed here. Their major mechanisms of action, key pharmacokinetic principles essential for their safe use and important adverse effects are explained. Each class of drug is also given context for effective clinical use.
Drugs used for the treatment of heart failure and for management of arrhythmias are discussed. Their major mechanisms of action, key pharmacokinetic principles essential for their safe use, and important adverse effects are explained. Each class of drug is also given context for effective clinical use.
Drugs used for the treatment of hypertension and for management of angina are discussed. Their major mechanisms of action, key pharmacokinetic principles essential for their safe use, and important adverse effects are explained. Each class of drug is also given context for effective clinical use.
Drugs used for the treatment of hyperlipidaemias, to reduce platelet aggregation and to achieve thrombolysis are discussed. Their major mechanisms of action, key pharmacokinetic principles essential for their safe use, and important adverse effects are explained. Each class of drug is also given context for effective clinical use.
Drugs used for the treatment of heart failure and for management of arrhythmias are discussed. Their major mechanisms of action, key pharmacokinetic principles essential for their safe use, and important side effects are explained. Each class of drug is also given context for effective clinical use.
Drugs used for the treatment of hyperlipidaemias, to reduce platelet aggregation and to achieve thrombolysis are discussed. Their major mechanisms of action, key pharmacokinetic principles essential for their safe use, and important side effects are explained. Each class of drug is also given context for effective clinical use.
Drugs used for the treatment of hypertension and for management of angina are discussed. Their major mechanisms of action, key pharmacokinetic principles essential for their safe use, and important side effects are explained. Each class of drug is also given context for effective clinical use.
Following myocardial infarction (MI), mortality and the incidence of recurrent non-fatal MI is highest in the first 4-6 weeks (Figure 1). Subsequently, 5-10% of those aged 50-70 years die each year (compared with an average 1% of the general population) and 3-4% suffer a further non-fatal MI. Survival is worse with increasing age, greater left ventricular (LV) dysfunction and recurrent MI. MI can...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.